Role of faecal calprotectin as a predictor of endoscopic activity in paediatric patients with ulcerative colitis

Shentova, Rayna; Baycheva, M.; Hadjiiski, P; Kofinova, Denitza; Yaneva, Penka

doi:10.1016/j.gastre.2019.08.005

Cited by 2 publications

(2 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This was confirmed by Shentova R et al that in pediatric patients with UC; cut-off point 285 µg/g of FC correlated with exacerbation of the disease in endoscopic studies, despite no clinical progression. 41…”

Section: Discussionmentioning

confidence: 99%

Fecal Calprotectin as early predictor for screening and relapse in pediatric chronic diarrhea in India

Deepika¹,

Veeraiah²,

Naveed³

et al. 2021

IJMPO

View full text Add to dashboard Cite

: IBS and IBD are two abdomen ailments commonly seen in children. IBD is a life-long disorder that includes two major forms of chronic illness UC and CD, IBS may occur when the bowel is sensitive to specific foods or other triggers like stress. The aims of the study is to investigate clinical usefulness of FC as early predictor for screening and differentiating IBD and IBS and to monitor the treatment for relapse and remission in pediatric Indian population. This was hospital based observational cohort study, conducted over a period of twelve months from January 2019 to December 2019 Total 325 patients attending OPD were included in the study, in children between 1-18years in which FC was measured using commercially available CLIA kit. HB, ESR, Hscrp were also assessed, these patients were followed up. Patients were grouped asGroup I: IBS: 115(50:65M/F), Group II: 185 IBD, had Subgroup I:116 CD(48:68M/F);Group A: 62.7% presented with relapse Group B: 37.3% had disease in remission Subgroup II: 69 patients had UC(31:38 M/F); Group A: 60.9% had relapse and Group B: 39.1% in remission after follow up. Subgroup III: Others were 25(7.7%). In Study I: Levels of FC were significantly lower in patients with group I when compared to group II. In Subgroup I & Subgroup II Group A had higher FC levels when compared to group B. In Study II: A significant difference (P<0.001) and lower values of the FC, ESR, Hs-crp, frequency of stools in IBS than in CD and UC patients were observed. In Study III: FC in IBD has positive correlation (p<0.01), with the activity of the inflammatory disorder, HB, ESR, Hs-CRP and with increased frequency of diarrhea. In Study IV Fecal calprotectin value of ≥100 ug/g was diagnostic of IBD with sensitivity of 94.1%, specificity of 82.2%, PPV of 86.32%, NPV of 80.39%. The present study showed that the determination of FC assists to differentiate between IBD and IBS also useful in monitoring of remission and in early prediction of relapse in pediatric IBD.

show abstract

Section: Discussionmentioning

confidence: 99%

Fecal Calprotectin as early predictor for screening and relapse in pediatric chronic diarrhea in India

Deepika¹,

Veeraiah²,

Naveed³

et al. 2021

IJMPO

View full text Add to dashboard Cite

show abstract

“…Many studies show that changes in calprotectin levels may precede both clinical symptoms and endoscopic changes. This was confirmed in pediatric patients with UC; high values (mean cutoff point 285 µg/g) of FC correlated with exacerbation of the disease in endoscopic studies, despite no clinical progression [69, 70]. Unfortunately, FC correlates worse with lesions in the small intestine, and thus, it cannot replace capsule endoscopy [71].…”

Section: Monitoring the Effectiveness Of Therapymentioning

confidence: 96%

Usefulness of Testing for Fecal Calprotectin in Pediatric Gastroenterology Clinical Practice

et al. 2020

View full text Add to dashboard Cite

Gastrointestinal tract symptoms such as abdominal pain, constipation, diarrhea, and fever are frequent causes of visits to the pediatrician. The increasing prevalence of chronic gastrointestinal tract diseases, and the falling median age of their onset, indicate the need to identify new diagnostic methods that can differentiate inflammatory bowel diseases from other gastrointestinal tract conditions. A promising non-invasive and useful marker of intestinal inflammation is fecal calprotectin. The manuscript summarizes currently available information on the use of fecal calprotectin in the diagnosis and monitoring of inflammatory bowel disease in children. It also attempts to determine the effect of concentration on its course of action. Incorporating fecal calprotectin (FC) testing within the framework of primary medical care can decrease the number of children unnecessarily referred for endoscopic or radiologic examination. FC screening benefits patients by reducing any delay in diagnosis and avoiding unnecessary exposure to endoscopy, and benefits physicians by reducing pressure on endoscopy testing and assisting the decision. The present paper emphasizes the role of fecal calprotectin as a non-invasive marker for monitoring disease activity and efficacy of therapy, and predicting postoperative relapses, primarily in patients with IBD.

show abstract

Role of faecal calprotectin as a predictor of endoscopic activity in paediatric patients with ulcerative colitis

Cited by 2 publications

References 21 publications

Fecal Calprotectin as early predictor for screening and relapse in pediatric chronic diarrhea in India

Fecal Calprotectin as early predictor for screening and relapse in pediatric chronic diarrhea in India

Usefulness of Testing for Fecal Calprotectin in Pediatric Gastroenterology Clinical Practice

Contact Info

Product

Resources

About